A. Nasser

发表

A Randomized, Double-Blind, Placebo-Controlled Trial of RBP-8000 in Cocaine Abusers: Pharmacokinetic Profile of RBP-8000 and Cocaine and Effects of RBP-8000 on Cocaine-Induced Physiological Effects

P. Fudala, C. Heidbreder, A. Nasser, 2014, Journal of addictive diseases.

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder

R. Findling, J. Hull, S. Schwabe, 2021, Journal of clinical psychopharmacology.

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.

R. Findling, J. Hull, S. Schwabe, 2021, Clinical therapeutics.

Liquid chromatography/tandem mass spectrometry method for simultaneous determination of cocaine and its metabolite (-)ecgonine methyl ester in human acidified stabilized plasma samples.

P. Fudala, C. Heidbreder, A. Nasser, 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder

M. Fava, J. Hull, A. Nasser, 2021, International journal of clinical practice.

A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence

M. Greenwald, P. Fudala, R. Gomeni, 2014, Clinical Pharmacokinetics.

Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers

P. Fudala, C. Heidbreder, A. Nasser, 2015, Clinical Pharmacokinetics.

Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (QelbreeTM) in Healthy Adult Subjects

S. Schwabe, A. Nasser, Tesfaye Liranso, 2021, European journal of drug metabolism and pharmacokinetics.

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults

S. Schwabe, A. Nasser, T. Adewole, 2020, Clinical Drug Investigation.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

S. Schwabe, A. Nasser, A. Childress, 2022, CNS Drugs.

Closing the gap: unmet needs of individuals with impulsive aggressive behavior observed in children and adolescents

J. Buitelaar, R. Findling, J. Newcorn, 2020, CNS Spectrums.

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.

R. Findling, J. Hull, S. Schwabe, 2021, Psychopharmacology bulletin.

Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults

S. Schwabe, A. Nasser, T. Adewole, 2021, Clinical pharmacology in drug development.

Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial

S. Faraone, R. Gomeni, A. Nasser, 2022, Psychiatry Research.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

S. Schwabe, A. Nasser, A. Childress, 2022, CNS Drugs.

Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study

M. Fava, D. Henderson, P. Fudala, 2016, Journal of clinical psychopharmacology.

Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment

P. Fudala, R. Gomeni, C. Heidbreder, 2014, Clinical Pharmacokinetics.

A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone

P. Fudala, R. Gomeni, C. Heidbreder, 2013, Journal of clinical pharmacology.

Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry.

C. Heidbreder, Xiaohua Li, A. Nasser, 2016, Journal of pharmaceutical and biomedical analysis.

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

M. Greenwald, P. Fudala, C. Heidbreder, 2016, Journal of clinical psychopharmacology.

Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree®): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder

S. Faraone, R. Gomeni, A. Nasser, 2023, Brain and behavior.

A Double-Blind, Randomized Study of Extended-Release Molindone for Impulsive Aggression in ADHD

R. Findling, S. Schwabe, A. Nasser, 2020, Journal of attention disorders.

Population Pharmacokinetic Modeling After Repeated Administrations of RBP‐6000, a New, Subcutaneously Injectable, Long‐Acting, Sustained‐Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder

R. Gomeni, C. Heidbreder, A. Nasser, 2016, Journal of clinical pharmacology.

a Multiple-dose Study Of Blockade Of Opioid Subjective Effects By Subcutaneous Injections Of Depot Buprenorphine In Subjects With Opioid Use Disorder : pii-054

M. Greenwald, P. Fudala, C. Heidbreder, 2015 .

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults

A. Nasser, T. Adewole, Nicholas Fry, 2021, Journal of clinical psychopharmacology.

A Phase III, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Once-Daily SPN-812 (Viloxazine Extended-Release) in the Treatment of Attention-Deficit/Hyperactivity Disorder in School-age Children.

R. Findling, J. Hull, S. Schwabe, 2020, Clinical therapeutics.

112 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P302): Efficacy and Safety of Extended-Release Viloxazine in Adolescents with ADHD

J. Hull, S. Schwabe, A. Nasser, 2020, CNS Spectrums.

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

R. Findling, J. Newcorn, S. Schwabe, 2019, Journal of attention disorders.

Application of the Impulsive Aggression Diary in Adolescents with Attention-Deficit/Hyperactivity Disorder.

R. Findling, S. Schwabe, C. Evans, 2019, Journal of child and adolescent psychopharmacology.

A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression

R. Findling, S. Schwabe, A. Nasser, 2019, Postgraduate medicine.

Population pharmacokinetic modeling and simulation to guide dose selection for RBP‐7000, a new sustained‐release formulation of risperidone

P. Fudala, R. Gomeni, C. Heidbreder, 2015, Journal of clinical pharmacology.

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status

R. Findling, J. Newcorn, S. Schwabe, 2021, CNS Drugs.

Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials

S. Faraone, J. Hull, R. Gomeni, 2021, Psychiatry Research.

A Novel Assessment Tool for Impulsive Aggression in Children with Attention-Deficit/Hyperactivity Disorder

R. Findling, S. Schwabe, C. Evans, 2019, Journal of child and adolescent psychopharmacology.

Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials

S. Faraone, J. Hull, R. Gomeni, 2021, Pediatric Drugs.

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adole

M. Fava, S. Faraone, J. Hull, 2021, Journal of child and adolescent psychopharmacology.

A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder

S. Faraone, J. Hull, R. Gomeni, 2021, European Child & Adolescent Psychiatry.

The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials

J. Hull, A. Nasser, Z. Melyan, 2021, Neuropsychiatric disease and treatment.

Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation

S. Schwabe, R. Gomeni, A. Nasser, 2020, Clinical pharmacology : advances and applications.

CPAA_A_256972 135..147

S. Schwabe, R. Gomeni, A. Nasser, 2020 .

Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults.

M. Fava, S. Schwabe, R. Kleiman, 2020, The Journal of clinical psychiatry.